The co-inhibitory receptors that either differ significantly in patients with MS as compared to the HCs (TIGIT, LAG-3) or that predict MS outcome (LAG-3 and TIM-3) are associated with the immunoregulatory cytokine interleukin IL-10 (23–25). Here, IL10 is linked to myeloid sarcoma.